Ilana Graetz|Caitlin N. McKillop|Edward J. Stepanski|Gregory A. Vidal|Janeane N. Anderson|Lee S. Schwartzberg
Use of a web-based app to improve breast cancer symptom management and adherence for aromatase inhibitors: a randomized controlled feasibility trial
University of Tennessee Health Science Center|State University of New York College at Cortland|University of Tennessee Health Science Center|Vector Oncology (United States)|University of Tennessee Health Science Center|West Cancer Center|University of Tennessee Health Science Center|University of Tennessee Health Science Center|West Cancer Center|Vector Oncology (United States)
postmenopausal women hormone receptorpositive breast cancer longterm use aromatase inhibitors ais significantly reduces risk cancer recurrence improves survival still many patients nonadherent due adverse side effects conducted pilot randomized controlled trial test use webbased application app designed without weekly reminders patients report realtime symptoms ai use outside clinic visits builtin alerts patients oncology providers goal improve symptom burden medication adherence fortyfour women earlystage breast cancer new ai prescription randomized either appreminder weekly reminders use app app reminders group pre postassessment data collected participants participants appreminder group higher weekly app usage rate 74 vs 38 p 005 intervention reported higher ai adherence 8 weeks 100 vs 72 p 005 symptom burden increase higher app group compared appreminder group reach statistical significance weekly reminders use webbased app report ai adherence treatmentrelated symptoms demonstrated feasibility improved shortterm ai adherence may reduce symptom burden women breast cancer new ai prescription shortterm gains adherence persist lowcost intervention could improve survival outcomes women breast cancer larger longterm study examine ai adherence symptom burden improvements persist 5year treatment period